Let’s dive into some prime choices out of from the screener.<\/p>\n
Simply Wall St Value Rating: \u2605\u2605\u2605\u2605\u2606\u2606<\/p>\n
Overview: NewPrinces S.p.A. operates in the agri-food sector across Italy, Germany, the United Kingdom, and internationally with a market capitalization of approximately \u20ac730.14 million.<\/p>\n
Operations: NewPrinces generates revenue primarily from Foods (\u20ac743.01 million), Fish (\u20ac409.66 million), and Drinks (\u20ac391.74 million) segments, with significant contributions also from Oils and Dairy Products, each around \u20ac328-334 million.<\/p>\n
NewPrinces has demonstrated impressive growth, with earnings surging 133.5% over the past year, outpacing the Food industry’s 1.9%. The company reported a significant net income increase to \u20ac375.09 million from \u20ac160.63 million in the previous year, driven by sales rising to \u20ac2.96 billion from \u20ac1.64 billion. Despite a volatile share price recently, NewPrinces appears undervalued with a Price-To-Earnings ratio of 1.9x compared to Italy’s market average of 17.6x and maintains positive free cash flow at \u20ac397.72 million as of May 2026, although its debt-to-equity ratio has risen to 125.3% over five years.<\/p>\n
![\"BIT:NWL](\"https:\/\/www.europesays.com\/europe\/wp-content\/uploads\/2026\/05\/94aa377492c0dbec9fd4719ff2424978.png\")
BIT:NWL Earnings and Revenue Growth as at May 2026 <\/p>\n
Simply Wall St Value Rating: \u2605\u2605\u2605\u2605\u2605\u2606<\/p>\n
Overview: Pharmanutra S.p.A. is a nutraceutical company involved in the research, development, and marketing of food supplements and medical devices across Europe, the Middle East, Far East, North America, South America, and internationally with a market cap of \u20ac842.62 million.<\/p>\n
Operations: Pharmanutra generates revenue primarily through the sale of food supplements and medical devices across various international markets. The company’s financial performance includes a market capitalization of \u20ac842.62 million, reflecting its scale in the nutraceutical sector.<\/p>\n
Pharmanutra, a promising name in the European market, has shown impressive growth with earnings rising 20.4% last year, outpacing the industry’s 2.8%. The company’s net income for Q1 2026 was \u20ac3.46 million, up from \u20ac2.44 million in the same period last year, alongside revenues of \u20ac33.4 million compared to \u20ac26.82 million previously. Despite an increased debt-to-equity ratio from 3.2% to 26.7% over five years, Pharmanutra’s cash exceeds its total debt and interest payments are well covered at 203 times EBIT, indicating robust financial health and potential for continued growth in the personal products sector.<\/p>\n
BIT:PHN Earnings and Revenue Growth as at May 2026 <\/p>\n
Simply Wall St Value Rating: \u2605\u2605\u2605\u2605\u2605\u2605<\/p>\n
Overview: Realia Business, S.A. is involved in the development, management, and rental of real estate activities in Spain and Romania with a market capitalization of \u20ac1.55 billion.<\/p>\n
Operations: The company generates revenue primarily from rental property (\u20ac146.97 million) and real estate development (\u20ac182.60 million). Net profit margin stands out as a key metric, reflecting the company’s profitability after accounting for all expenses.<\/p>\n
Realia, a promising player in the European real estate sector, has been making waves with its robust financial performance. The company reported net income of \u20ac129.4 million for 2025, up from \u20ac74.24 million the previous year, showcasing impressive earnings growth of 74.3%, outpacing the industry average of 51.3%. Trading at approximately 16% below its estimated fair value suggests potential upside for investors seeking value opportunities. With a satisfactory net debt to equity ratio of 24.7% and interest payments well covered by EBIT at 5.5 times, Realia’s financial health appears solid despite recent shareholder dilution concerns.<\/p>\n
BME:RLIA Earnings and Revenue Growth as at May 2026 Next Steps Seeking Other Investments? <\/p>\n
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.<\/p>\n
Companies discussed in this article include BIT:NWL BIT:PHN and BME:RLIA.<\/p>\n
Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"As the pan-European STOXX Europe 600 Index navigates a week marked by geopolitical tensions and strong corporate earnings,…\n","protected":false},"author":2,"featured_media":39411,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[6351,13078,525,4,15,1832,19266,1088,4685,1838,351],"class_list":{"0":"post-40398","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-europe","8":"tag-cautiously-optimistic","9":"tag-corporate-earnings","10":"tag-earnings-growth","11":"tag-europe","12":"tag-european","13":"tag-growth-opportunities","14":"tag-impressive-growth","15":"tag-market-capitalization","16":"tag-market-volatility","17":"tag-potential","18":"tag-revenue-growth"},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/posts\/40398","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/comments?post=40398"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/posts\/40398\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/media\/39411"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/media?parent=40398"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/categories?post=40398"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/europe\/wp-json\/wp\/v2\/tags?post=40398"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}